Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessMethodology

Modeling AIDS survival after initiation of antiretroviral treatment by Weibull models with changepoints

Constantin T Yiannoutsos email

Division of Biostatistics, Indiana University School of Medicine,401 W. 10th Street, Suite 3000, Indianapolis, USA

author email corresponding author email

Journal of the International AIDS Society 2009, 12:9doi:10.1186/1758-2652-12-9

Published: 26 June 2009

Abstract

Background

Mortality of HIV-infected patients initiating antiretroviral therapy in the developing world is very high immediately after the start of ART therapy and drops sharply thereafter. It is necessary to use models of survival time that reflect this change.

Methods

In this endeavor, parametric models with changepoints such as Weibull models can be useful in order to explicitly model the underlying failure process, even in the case where abrupt changes in the mortality rate are present. Estimation of the temporal location of possible mortality changepoints has important implications on the effective management of these patients. We briefly describe these models and apply them to the case of estimating survival among HIV-infected patients who are initiating antiretroviral therapy in a care and treatment programme in sub-Saharan Africa.

Results

As a first reported data-driven estimate of the existence and location of early mortality changepoints after antiretroviral therapy initiation, we show that there is an early change in risk of death at three months, followed by an intermediate risk period lasting up to 10 months after therapy.

Conclusion

By explicitly modelling the underlying abrupt changes in mortality risk after initiation of antiretroviral therapy we are able to estimate their number and location in a rigorous, data-driven manner. The existence of a high early risk of death after initiation of antiretroviral therapy and the determination of its duration has direct implications for the optimal management of patients initiating therapy in this setting.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.